Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts
Mar 02 2020
•
By
Joseph Haas
Forty Seven's anti-CD47 candidates add new potential to Gilead's IO pipeline
More from Deals
More from Business